These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33292530)

  • 1. Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study.
    Angulo M; Abuzzahab MJ; Pietropoli A; Ostrow V; Kelepouris N; Tauber M
    Int J Pediatr Endocrinol; 2020 Nov; 2020(1):20. PubMed ID: 33292530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
    Ross JL; Lee PA; Gut R; Germak J
    Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry.
    Lee PA; Ross J; Germak JA; Gut R
    Int J Pediatr Endocrinol; 2012 Jun; 2012(1):15. PubMed ID: 22682146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program.
    Miller BS; Ross J; Ostrow V
    Int J Pediatr Endocrinol; 2020; 2020():19. PubMed ID: 33042202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program.
    Backeljauw P; Blair JC; Ferran JM; Kelepouris N; Miller BS; Pietropoli A; Polak M; Sävendahl L; Verlinde F; Rohrer TR
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2653-2665. PubMed ID: 36947589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program.
    Sävendahl L; Polak M; Backeljauw P; Blair J; Miller BS; Rohrer TR; Pietropoli A; Ostrow V; Ross J
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4730-4742. PubMed ID: 31305924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis.
    Ross J; Fridman M; Kelepouris N; Murray K; Krone N; Polak M; Rohrer TR; Pietropoli A; Lawrence N; Backeljauw P
    J Endocr Soc; 2023 Mar; 7(5):bvad026. PubMed ID: 36936713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
    J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.
    Rose SR; Reeves G; Gut R; Germak J
    J Pediatr; 2015 Dec; 167(6):1389-96. PubMed ID: 26394822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program.
    Lee PA; Ross JL; Pedersen BT; Kotnik P; Germak JA; Christesen HT
    Int J Pediatr Endocrinol; 2015; 2015(1):17. PubMed ID: 26351466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program.
    Biller BMK; Höybye C; Carroll P; Gordon MB; Birkegård AC; Kelepouris N; Nedjatian N; Weber MM
    Pituitary; 2021 Aug; 24(4):611-621. PubMed ID: 33709288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program.
    Ross JL; Lee PA; Gut R; Germak J
    Int J Pediatr Endocrinol; 2015; 2015(1):1. PubMed ID: 25904938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone replacement in adults: Real-world data from two large studies in US and Europe.
    Weber MM; Gordon MB; Höybye C; Jørgensen JOL; Puras G; Popovic-Brkic V; Molitch ME; Ostrow V; Holot N; Pietropoli A; Biller BMK
    Growth Horm IGF Res; 2020 Feb; 50():71-82. PubMed ID: 31972476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies.
    Lee PA; Sävendahl L; Oliver I; Tauber M; Blankenstein O; Ross J; Snajderova M; Rakov V; Pedersen BT; Christesen HT
    Int J Pediatr Endocrinol; 2012 Jul; 2012(1):22. PubMed ID: 22788856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®.
    Lee PA; Germak J; Gut R; Khutoryansky N; Ross J
    Int J Pediatr Endocrinol; 2011 Jul; 2011(1):6. PubMed ID: 21899782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER.
    Biller BMK; Höybye C; Ferran JM; Kelepouris N; Nedjatian N; Olsen AH; Weber MM; Gordon MB
    J Endocr Soc; 2023 May; 7(6):bvad054. PubMed ID: 37197408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study.
    Polak M; Blair J; Kotnik P; Pournara E; Pedersen BT; Rohrer TR
    Eur J Endocrinol; 2017 Nov; 177(5):421-429. PubMed ID: 28780521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
    Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
    Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.